August 12, 2016

Breast Cancer

The Gabrail Cancer Center currently has many Clinical Trial opportunities. For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or email CSmith@GabrailCancerCenter.com.

Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance on First Line Palbociclib Plus Aromatase Inhibitor Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

A Phase 1b Clinical Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, as a Chemoprotection Agent in Patients with TP53-mutated, HER2 Negative Stage IIa – IIIb Breast Cancer Receiving Neoadjuvant Chemotherapy

Return to Clinical Trials at GCC